SAFE-PFO Trial Begins Patient Enrollment in Germany to Compare PFO Closure Devices
The SAFE-PFO trial has begun patient enrollment in Germany to compare two catheter-based devices, the Cocoon and Amplatzer PFO Occluders, for closing patent foramen ovale (PFO), a common heart defect linked to stroke risk. Led by Dr. Werner Scholtz at HDZ NRW, the randomized study aims to enroll 1,260 patients across 60 European centers, monitoring each for 12 months. The trial addresses the need for safe, minimally invasive treatments for congenital heart defects affecting millions worldwide.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (52/100). Lens Score 38/100.
Outlets measured: businessstandard, thetribune. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thetribune broke this story on 2 Sept, 08:45 am. Other outlets followed.